Longevity Medicine
Multi-Cancer Early Detection Blood Tests: What They Can and Can't Do
Published · Haute MD Editorial Team
A multi-cancer early detection (MCED) test is a blood test that looks for signals from many types of cancer at once, usually by analyzing fragments of DNA that tumors shed into the bloodstream. The best-known, GRAIL's Galleri, is available in the U.S. by prescription. As of Oct. 21, 2026, it is not FDA-approved: an FDA advisory panel voted in favor of approval on Sept. 23, 2026, and the agency's decision is pending. In the two large studies FDA reviewed, Galleri found roughly one in three cancers diagnosed within a year. False positives were uncommon, and it missed most early-stage cancers. It does not replace mammograms, colonoscopy or other recommended screening.
How MCED tests work
A standard blood draw: the lab isolates cell-free DNA (cfDNA) from plasma. Methylation patterns: Galleri reads chemical "methylation" marks on that DNA that differ between cancer and normal cells. Two-part result: "Cancer Signal Detected" or "No Cancer Signal Detected"; and, if a signal is found, a predicted Cancer Signal Origin (the likely organ or tissue), which guides follow-up imaging and tests. It is a screening test, not a diagnosis. A positive result must be confirmed with standard diagnostic tests. A negative result does not rule out cancer.
FDA status (as of Oct. 21, 2026)
Breakthrough Device designation: August 2018 (FDA executive summary). Earlier version launched by prescription in the U.S. as a lab-developed test: June 2021 (FDA executive summary). Premarket Approval (PMA) application submitted: Jan. 29, 2026 (GRAIL; FDA executive summary). FDA advisory panel vote, Sept. 23, 2026: safety 10–0; effectiveness 6–4; benefits outweigh risks 7–2 (1 abstention) (FDA 24-hour panel summary). FDA decision: pending. FDA is not bound by the panel's vote (GRAIL, Sept. 23, 2026). FDA's briefing document states there are currently no FDA-authorized devices for screening for multiple types of cancer. In the meantime, Galleri is run in GRAIL's CLIA-certified laboratory. GRAIL's own disclosure notes it "has not been cleared or approved by the Food and Drug Administration." At the panel, members said Galleri's value is greatest for cancers that have no recommended screening test, and that it should not replace established screening. Many doubted that the word "early" in the proposed label was supported.
What the studies show
FDA reviewed two pivotal studies, PATHFINDER 2 (U.S., ages 50+) and NHS-Galleri (England, ages 50–77). "12-month episode sensitivity" means the share of cancers diagnosed within a year of the test that Galleri flagged. Cancers found (12-month episode sensitivity): 35.0% in PATHFINDER 2 and 31.6% in NHS-Galleri. Specificity (true negatives): 99.85% and 99.74%. Positive predictive value (a positive turned out to be cancer): 77.0% and 66.2%. Stage I cancers found: 21.4% and 13.6%. Stage IV cancers found: 63.2% and 60.0%. (Source: FDA Executive Summary for the Sept. 23, 2026 panel.)
False positives, organ prediction and missed cancers
False positives were uncommon but real. In PATHFINDER 2 the false-positive rate was 0.15%, about 1 in 670 people without cancer. People with a false positive took a median 75 days to reach a diagnostic answer, versus 36 days for those whose cancer was confirmed. The organ prediction is usually right: among true positives in PATHFINDER 2, the predicted cancer signal origin was correct 94.3% of the time. Cancers that already have screening tests are often missed. In NHS-Galleri, Galleri flagged 19.1% of breast cancers and 10.7% of prostate cancers diagnosed within a year. In PATHFINDER 2 the figures were 26.4% and 10.7%. Number needed to screen: in PATHFINDER 2, about 202 people were tested for each cancer found.
Does it save lives? Not yet known
NHS-Galleri's primary goal was not met. The trial randomized about 142,000 people in England to Galleri plus usual screening or usual screening alone. Its primary goal, fewer stage III–IV diagnoses across three annual rounds for 12 deadly cancers, was not met (GRAIL, May 30, 2026). Stage IV results: GRAIL reports a secondary finding of fewer stage IV diagnoses in later rounds: 22% in round two and 26% in round three for the 12 cancers. For the first round, FDA's summary shows an incidence rate ratio of 0.87 (95% CI 0.68–1.13), with no formal statistical testing. No mortality data yet: no study has yet shown that an MCED test reduces cancer deaths. NCI's Vanguard Study: the National Cancer Institute is running this feasibility study, enrolling up to 24,000 people, to design a larger trial that would test exactly that. It uses two other assays: ClearNote Health's Avantect and Guardant Health's Shield MCD.
Who pays: Medicare law and guidelines
USPSTF: the U.S. Preventive Services Task Force has no recommendation for MCED tests. Its cancer screening recommendations cover breast, cervical, colorectal, lung and prostate cancer. Medicare: Section 6221 of the Consolidated Appropriations Act, 2026 (P.L. 119-75, signed Feb. 3, 2026) creates a Medicare benefit for MCED screening tests furnished on or after Jan. 1, 2029, but only for tests that are FDA-cleared or approved and that Medicare finds reasonable and necessary through a national coverage determination. It limits testing to once every 11 months, sets age limits, and says the benefit does not change coverage of other cancer screenings. Private insurance: coverage varies. Ask your insurer and the ordering physician.
Who might consider an MCED test
FDA reviewed Galleri for adults 50 and older. Questions worth discussing with your doctor: Am I up to date on guideline screenings (mammography, colonoscopy or stool testing, cervical screening, lung CT if eligible, PSA discussion)? An MCED test is meant to be used in addition to these. If the test is positive, what is the follow-up plan, which scans, and who coordinates them? How would a false positive or a false negative affect my decisions? Is this test FDA-approved yet, and what does my insurance cover?
MCED vs. full-body MRI
Both are "look-for-anything" screens with similar trade-offs: incidental findings, follow-up testing and limited outcome data. An MCED test reads blood for a cancer signal. A full-body MRI images organs and can find non-cancer findings too. See What is full-body MRI screening? and Prenuvo vs. hospital full-body MRI.
Find a doctor
Browse longevity and concierge medicine physicians or Find a Doctor on Haute MD. Featured doctors: Dr. Kern Brar, a board-certified internist whose concierge practice in Encinitas, Oceanside and La Jolla, Calif., lists Galleri testing among its preventive diagnostics; and Dr. Ari Cohen, a board-certified internist offering preventive primary care in Aventura, Fla. Haute MD members are featured through paid membership. Membership is not an endorsement or a ranking.
Sources
1. FDA, Executive Summary: GRAIL Inc., Galleri, Molecular and Clinical Genetics Panel, Sept. 23, 2026. https://www.fda.gov/media/194909/download 2. FDA, Molecular and Clinical Genetics Panel, Sept. 23, 2026, 24 Hour Summary. https://www.fda.gov/media/195032/download 3. FDA, Sept. 23, 2026 Molecular and Clinical Genetics Panel meeting announcement. https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting 4. GRAIL, "FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test" (Sept. 23, 2026). https://grail.com/press-releases/fda-advisory-committee-votes-in-favor-of-approval-of-grails-galleri-multi-cancer-early-detection-test/ 5. GRAIL, "GRAIL Reports Full Results From NHS-Galleri Trial" (May 30, 2026). https://grail.com/press-releases/grail-reports-full-results-from-nhs-galleri-trial-demonstrating-substantial-reduction-in-stage-iv-cancer-diagnoses-at-2026-asco-annual-meeting/ 6. GRAIL, "GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026" (Oct. 5, 2026). https://grail.com/press-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-edcc-and-esmo-congress-2026/ 7. openFDA device PMA dataset (no Galleri record as of Oct. 21, 2026). https://open.fda.gov/apis/device/pma/ 8. Consolidated Appropriations Act, 2026 (H.R. 7148), §6221, Medicare coverage of multi-cancer early detection screening tests; P.L. 119-75. https://www.congress.gov/bill/119th-congress/house-bill/7148 9. National Cancer Institute, Division of Cancer Prevention, Vanguard Study. https://prevention.cancer.gov/research-areas/networks-consortia-programs/csrn/vanguard-study
Medical disclaimer
This page is for general education and is not medical advice. Talk with a qualified physician about your situation.
Frequently Asked Questions
Is the Galleri test FDA-approved?
Not as of Oct. 21, 2026. An FDA advisory panel voted in favor on Sept. 23, 2026, and FDA's decision is pending. The test is currently offered by prescription as a laboratory-developed test.
How accurate is Galleri?
In FDA-reviewed studies it detected about 32–35% of cancers diagnosed within a year, with specificity near 99.8% and a positive predictive value of 66–77%. It detected far fewer stage I cancers (14–21%).
Can an MCED test replace a colonoscopy or mammogram?
No. FDA's panel said it should not replace guideline-recommended screening, and it misses many cancers those tests find.
What happens after a positive result?
Diagnostic testing guided by the predicted cancer signal origin, typically imaging and specialist evaluation. Some positives are false positives.
Does Medicare cover multi-cancer blood tests?
A new law creates coverage starting Jan. 1, 2029, but only for FDA-cleared or -approved tests that Medicare finds reasonable and necessary, with age and frequency limits.
Do MCED tests reduce cancer deaths?
That has not yet been shown. NHS-Galleri missed its primary stage III–IV goal, and longer-term and NCI-funded studies are under way.
Featured Haute MD Physicians
Browse Haute MD physiciansGet Help Now
Speak with a Haute MD Longevity Medicine physician
Are you a Longevity Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · LONGEVITY MEDICINE
What Is Executive Health Screening?
Executive health screening provides comprehensive annual health assessment for high-performance individuals. Learn what is included and where to get it.
Read GuideGuide · LONGEVITY MEDICINE
What Is Preventive Medicine?
Preventive medicine focuses on avoiding disease before it develops through screening, lifestyle optimization, and early intervention. Learn what preventive medicine includes.
Read GuideGuide · LONGEVITY MEDICINE
What Blood Tests Are Important for Longevity?
The most important longevity blood tests include ApoB, Lp(a), fasting insulin, hsCRP, and a comprehensive hormonal panel. Learn what to ask your doctor to order.
Read Guide